Filipa Lynce, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results from an analysis of biopsy samples from the ALAVE trial (NCT03964532), which investigated induction talazoparib followed by talazoparib and avelumab in patients with advanced breast cancer. Following RNA sequencing and protein analyses, responders and non-responders had differential expression of CD8 T cells and patients with BRCA1/2-mutant breast cancer tended to respond more to treatment. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.